Key result
Left atrial appendage closure devices provide a promising non-pharmacological alternative to systemic anticoagulation for stroke prevention in patients with atrial fibrillation.
Why the study?
Do catheter-based left atrial appendage occlusion devices prevent thromboembolic stroke in patients with atrial fibrillation compared to systemic anticoagulation or antiplatelet therapy?
Population
Patients with atrial fibrillation at risk of cardioembolic stroke, including those with and without…
Comparison
Endovascular and epicardial catheter-based left… vs Systemic anticoagulation or antiplatelet…
Design
Review
Authors
Loading...
May support LAA closure in anticoagulation-intolerant AF patients; leaves open need for definitive RCTs versus NOACs.
Do catheter-based left atrial appendage occlusion devices prevent thromboembolic stroke in patients with atrial fibrillation compared to systemic anticoagulation or antiplatelet therapy?
Catheter-based LAA occlusion devices represent a promising, non-pharmacological alternative for stroke prevention in patients with atrial fibrillation, particularly those with contraindications to long-term anticoagulation.
Kapur et al. (2014) conducted a review in Atrial fibrillation. Left atrial appendage closure devices vs. Systemic anticoagulation was evaluated. Left atrial appendage closure devices provide a promising non-pharmacological alternative to systemic anticoagulation for stroke prevention in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: